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ferential extent of RF injury between one and two cycle treatment groups.
CONCLUSIONS The Terumo Iberis RDN system was demonstrated
to be safe following single or double cycle RF ablation. NE decrease
following RDN was demonstrated at 7, 30, and 90 days compared to
naïve controls, suggesting efﬁcient nerve ablation with the device as
intended for human use.
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BACKGROUND The blood pressure (BP) response to renal denervation
(RDN) is highly variable. In addition, the changes in renal artery (RA)
dimensions induced by RDN have rarely been quantiﬁed and never
been related to BP changes.
METHODS We investigated RAs of 16 patients (7 females, 11 diabetics,
mean age 62.6 years) pre and post RDN (Symplicity Flex in 9 pts,
Symplicity Spyral in 7 pts; both Medtronic Inc) with intravascular ul
trasound (Atlantis pro, Boston Scientiﬁc iLab). IVUS images were
analyzed with QCU CMS research software (LUMC) yielding global
measures of RA size (RA vessel volume VV, lumen volume LV, wall
volume WV), and measures of most pronounced focal changes (min
imum and maximum vessel area VA, lumen area LA and wall burden
WB) Figure. Patients were followed with ofﬁce and 24 hour blood
pressure monitoring at month 1, 3, 6, and 12.
RESULTS Pre RDN, 24 hour BP was 153/88 mm Hg, mean number of
ablation points was 11.3 (SD 3.4). After 1, 3, 6, and 12 months, 24 hour
BP decreased by 12/7, 6/4, 17/9, and 21/11 mm Hg, respectively. RDN
induced a non signiﬁcant decrease in RA vessel volume of 5.6 (SD 9.8)
%, a signiﬁcant decrease of RA lumen volume of 8.8 (SD 10.7)%, and a
non signiﬁcant increase of RA wall volume of 6.1 (SD 10.9) %. Max and
min LA decreased signiﬁcantly by 7.3 (SD 9.4) and 10.5 (14.3) %,
respectively, as did min VA by 7.1 (12.5) %. Max vessel area and min
and max wall burden did not change signiﬁcantly. Women had smaller
RAs, which was related to their lower body height. Changes in RA size
were similar between men and women, as were changes in blood
pressure. ABPM based BP change at 1 (SBP, DBP), 3 (SBP, DBP), 6 (DBP)
and 12 (DBP) months was signiﬁcantly and directly related to changes
in min LA and min VA (correlation coeffﬁcients 0.63 0.80, p values
0.002 0.02). At 1 year, decrease in SBP was related to increase in wall
volume post RDN (r¼ 0.88, p¼0.004). Patients with a decrease in
minimal VA post RDN above the median had a signiﬁcantly better BP
response at 1 and 3 months. Patients with an increase in WV post RDN
had a signiﬁcantly better SBP response at 6 and 12 months.CONCLUSIONS RDN leads to effects on RA dimensions (decrease in
vessel and lumen size, increase in wall thickness), which can be
quantiﬁed by IVUS. A higher degree of changes may be associated
with a better BP response to the procedure.
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BACKGROUND Renal artery RF ablation is under investigation for the
treatment of hypertension. Recent research suggests lesion anatomic
placement may impact efﬁcacy of RF catheter renal ablation. Due to the
closer proximity of renal sympathetic nerves in the distal vessel segments,
it has been suggested that treatment of the renal artery branches might
help to reduce variability in efﬁcacy. However, it is unclear whether
focused distal treatment of the main renal artery is as effective as branchþ
main renal artery treatment. This study was initiated to investigate the
overall performance of two RF renal nerve ablation systems as well as
ablation anatomic location within the main renal and or bifurcations.
METHODS Sixteen swine were treated unilaterally with either 8 le
sions in the branch renal arteries (BA) or 8 in the branch þ 4 in the
main renal artery (MA) with the Medtronic Spyral(TM) catheter (SP) or
in the MA alone with the St. Jude Medical EnligHTN(TM) catheter (EN)
in one of four arms: 1) SP8 8 BA lesions, 2) SP12 8 BA þ 4 MA lesions,
3) EN8 8 MA lesions, or 4) EN12 12 MA lesions. Treatment followed
manufacturers’ instructions for use & were performed by one proce
duralist. All lesions in the MA were placed as distal as possible without
overlapping treatment sites. Animals were euthanized at 14 days with
each serving as its own control for norepinephrine (NE) analysis.
RESULTS A total of 162 lesions (EN n¼80 & SP n¼82) were created. All re
sults are given asmean & StDev unless stated otherwise. Each arm showed
statistical signiﬁcant changes in NE (ng/g) between treated kidneys vs.
untreated contralateral control (C): EN8 125.0159.0 vs. EN8 C 461.284.1
(P¼0.010), EN12 22.9 14.7 vs. EN12 C 492.8 62.9 (P<0.001), SP8 106.1
78.4 vs. SP8 C 438.5 66.4 (P<0.001), SP12 72.5 79.8 vs. SP12 C 411.155
96.7 (P¼0.002). Therewereno statistically signiﬁcant differences in tissue
NE % reductions across each arm based on catheter, anatomic location, &
number of lesions: EN8 74 34%, EN12 95 3%, SP8 76 16%, SP12 82
17% (P¼0.494). Nerve count based on anatomic location & lesion pathol
ogy results will be presented.CONCLUSIONS There was no difference observed between the %
reduction in tissue NE levels comparing main renal artery distal
treatment with the EnligHTN catheter & branch þ main renal artery
treatment with the Spyral catheter.
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Renal denervation: more ablative points major reduction in blood
pressure?
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BACKGROUND Data published in the study Simplicity III reported
that the effectiveness of the procedure is directly related to the
number of ablative points with a threshold calculated as about 14
points. In our experience this threshold has been exceeded since we
use the device Enlightn St Jude whose conformation allows both a
more favorable contact of the electrodes with the vessel wall and the
possibility of varying those points more precisely. This result can be
achieved only beginning the ablation as distally as possible in the
renal arteries, performing the procedure even in the branches when
they have a minimum diameter of 4 mm. The purpose of our study
was to see if a larger number of points of ablation were related to a
greater effectiveness of the procedure.
METHODS In our center 29 patients (17 men. Average age 58.4  14
years) with resistant hypertension were submitted to transcatheter
renal denervation between November 2011 and May 2015. 12 patients
had signs of hypertensive vascular damage. All of them were taking an
average of 4 antihypertensive drugs in dosage ceiling, including a
diuretic. The values of mean arterial pressure were: 176/98  17/
14 mmHg. For all patients we used the femoral arterial access. All pa-
tients were treated with dual anti platelet therapy for 3/6 months after
the procedure. 7 patients had complex renal anatomy: 2 patients had
superior polar arteries, 1 patient presented one superior and one infe-
rior polar artery and 4 patients presented an early bifurcation (length of
the proximal segment <10 mm), all arteries had a diameter >4 mm. 16
patients, treated from March 2014 to May 2015, were treated with an
average of 24-36 ablative points overall comparedwith theﬁrst group of
patients in which the ablative points were only 16.
RESULTS All patients were treated successfully. Renal function
remained stable. The average pressure was reduced by about
15 mmHg at six months in the group of patients treated with 16
ablative points, whereas in patients treated with 24-36 ablative points
this reduction was approximately 27 mmHg. One patient of the ﬁrst
group was hospitalized for hypertensive crisis seven months after the
procedure, the values of blood pressure normalized after about one
year and are still stable. All patients have gradually reduced the
number of antihypertensive drugs (1-2 against 4 or more pre-proce-
dure). Computed tomography angiography of the patients with com-
plex renal vascular anatomy (6) and of the patients in which the
ablation was performed very distally and showed a more important
parietal notch of the renal artery after the procedure (16) documented
the absence of parietal complications three months after the
procedure.
CONCLUSIONS Our experience conﬁrms that renal denervation is an
effective procedure in the treatment of hypertensive patients re-
fractory to medical therapy. A larger number of ablative points seems
to be strongly related to an increased efﬁcacy of treatment.
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BACKGROUND Percutaneous renal artery denervation has been
shown to decrease blood pressure among patients with resistant
arterial hypertension. We present in this review a meta-analysis of
all randomized controlled trials evaluating effectiveness andcomplications of catheter-based RDN for blood pressure control in
patients with resistant hypertension.
METHODS We searched Pub Med, Cochrane and Scopus were systemati-
cally searched up for all RTCs up to June 2015. Primary outcomes were 6
months reduction of ofﬁce systolic and diastolic blood pressure. Secondary
outcomes were 24 hours systolic blood pressure reduction and more than
10mmHgsystolic bloodpressure reduction.Weusedﬁxedor randomEffect
analysis using the Cochrane Handbook of Systematic Reviews.
RESULTS Out of 860 articles, ﬁve RCTs were included. The pooled
data provided a total of 776 patients, being 476 in the RDN group and
300 patients in the control group with mean 6 months of follow-up.
Both groups had ofﬁce systolic and diastolic blood pressures signiﬁ-
cantly decreased (p<0.05). There was no signiﬁcant difference in SBP
reduction between the two groups but RDN had higher DBP reduction
(p<0.05). RDN group presented with a trend towards higher decrease
of 24-hours systolic blood pressure (mean reduction -5.22; p¼0.07).
RDN trended to present more patients who had  10 mmHg SBP
decrease (p ¼0.1) (Figure 1).CONCLUSIONS Resistant hypertension treated with catheter-based
RDN respond well to blood pressure reduction and with sustained
control. It is yet to be determined if some RDN catheters are capable to
provide more concise results and therefore lead to better procedural
outcomes. Therefore more randomized clinical data are warranted.
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BACKGROUND Percutaneous sympathetic renal artery denervation is
available for the treatment of patients with resistant hypertension and
preserved renal function. We investigated the safety and efﬁcacy of a
